Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Phase 3 Completed 389 enrolled Novo Nordisk A/S

RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in combination with insulin aspart for the control of blood glucose in patients with Type 2 diabetes.

Timeline

Start: 2005-03
Primary completion: 2005-12
Completion: 2005-12

Outcome

Met primary endpoint

paper the non-inferiority criterion was met at 26 weeks (LS mean [Det-Gla]: 0.207; 95% CI: 0.0149,0.3995). PMID 19565569 ↗

Publications

Results Raskin P, Gylvin T, Weng W, Chaykin L. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev. 2009 Sep;25(6):542-8. doi: 10.1002/dmrr.989.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	insulin detemir	Protein / enzyme biologic	—	—
Subject	insulin glargine	Protein / enzyme biologic	—	—
Background	insulin aspart	Protein / enzyme biologic	—	—